University of Chicago Medicine Comprehensive Cancer Center | Strategic Alliance Partners

January 11, 2022

Peter Riedell, MD, discusses unique data points of a landmark analysis conducted in mantle cell lymphoma.

December 22, 2021

Peter Riedell, MD, discusses the patient population and design of a dynamic landmark analysis conducted in patients with mantle cell lymphoma.

December 21, 2021

Peter Riedell, MD, discusses the effects of time to relapse on outcomes in mantle cell lymphoma.

December 16, 2021

Christine Bestvina, MD, discusses the emerging role of neoadjuvant chemoimmunotherapy in lung cancer.

December 06, 2021

Christine Bestvina, MD, discusses challenges with interpreting molecular reports in lung cancer.

October 25, 2021

Daniel Catenacci, MD, discusses navigating HER2 testing in gastric and gastroesophageal adenocarcinoma.

October 13, 2021

Daniel Catenacci, MD, discusses recent updates in gastroesophageal junction adenocarcinoma and esophageal squamous cell carcinoma.

September 24, 2021

Marina Chiara Garassino, MD, professor of Medicine, Hematology and Oncology, The University of Chicago Department of Medicine, discusses the clinical implications of the phase 2 VISION trial evaluating patients with MET exon 14 skipping mutation–positive non–small cell lung cancer.

September 23, 2021

Peter Riedell, MD, discusses the rationale to evaluate survival outcomes after transplant in mantle cell lymphoma.

September 01, 2021

Peter Riedell, MD, discusses the importance of identifying early relapse in patients with high-risk mantle cell lymphoma.

August 09, 2021

“Smarter screening” and a better understanding of the breast cancers women of color are more likely to develop are all crucial to helping these patients survive this disease at the same rates as their White counterparts.

June 23, 2021

Peter Riedell, MD, discusses the rationale for a study in mantle cell lymphoma, the clinical implications of the findings, and unanswered questions that future research efforts should aim to answer.

June 21, 2021

Patients with lung cancer were identified as an at-risk group for developing severe complications as a result of SARS-CoV-2 infection, and thoracic oncologists were fast to respond with the establishment of the Thoracic Cancers International COVID-19 Collaboration.

June 16, 2021

Michael R. Charlton, MD, MBBS, discusses the interaction between liver disease and hepatocellular carcinoma.

May 13, 2021

Marina Chiara Garassino, MD, discusses key safety protocols that were initiated for patients with cancer in Italy during the COVID-19 pandemic.

May 06, 2021

Olwen Hahn, MD, discusses the clinical significance of the KATHERINE and FeDeriCa trials in the treatment of patients with early-stage HER2-postive breast cancer.

May 03, 2021

Olwen Hahn, MD, discusses the impact of trastuzumab emtansine on the treatment of patients with HER2-positive breast cancer.

April 30, 2021

Olwen Hahn, MD, discusses the convenience of the fixed-dose combination of trastuzumab and pertuzumab in a subcutaneous formulation in HER2-positive breast cancer.

April 23, 2021

Olwen Hahn, MD, discusses future research directions with tucatinib (Tukysa) in the treatment of patients with breast cancer.

April 20, 2021

Michael R. Charlton, MD, MBBS, discusses the effects of the COVID-19 pandemic on hepatocellular carcinoma.